Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD/MAD of Niclosamide in Healthy Adults
NCT04705415Phase 1Completed
- Sponsor
- NeuroBo Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by NeuroBo Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at Day 14, Electrocardiogram Parameters at Day 14 and 4 more. Started Nov 2020; status: completed.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04705415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705415.